Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 89 entries
View as:

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03581786 Org: User:
Start: 10/18/18 End: 10/30/22 Due: 10/30/23

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05502393 Org: User:
Start: 07/26/22 End: 12/31/24 Due: 12/31/25

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Phase: N/A Priority: Normal
NCT ID: NCT05532800 Org: User:
Start: 02/28/22 End: 02/09/23 Due: 02/09/24

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05975268 Org: User:
Start: 08/28/23 End: 10/29/25 Due: 10/29/26

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04394975 Org: User:
Start: 08/20/20 End: 01/08/25 Due: 01/08/26

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04085276 Org: User:
Start: 12/21/18 End: 12/31/25 Due: 12/31/26

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06095583 Org: User:
Start: 11/15/23 End: 07/31/29 Due: 07/31/30

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04856631 Org: User:
Start: 04/06/21 End: 11/30/23 Due: 11/30/24

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Phase: N/A Priority: Normal
NCT ID: NCT05242588 Org: User:
Start: 01/26/22 End: 06/10/23 Due: 06/10/24

A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

Phase: N/A Priority: Normal
NCT ID: NCT04469673 Org: User:
Start: 05/23/19 End: 06/28/20 Due: 06/28/21

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05427396 Org: User:
Start: 08/09/22 End: 08/31/25 Due: 08/31/26

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase: N/A Priority: Normal
NCT ID: NCT02915432 Org: User:
Start: 12/31/16 End: 04/30/22 Due: 04/30/23

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT04797702 Org: User:
Start: 04/15/21 End: 02/26/24 Due: 02/26/25

A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05167279 Org: User:
Start: 12/16/21 End: 12/08/22 Due: 12/08/23

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05664971 Org: User:
Start: 02/09/23 End: 11/17/25 Due: 11/17/26

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03086174 Org: User:
Start: 03/31/17 End: 12/31/20 Due: 12/31/21

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT06250062 Org: User:
Start: 01/12/24 End: 10/08/25 Due: 10/08/26

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05061628 Org: User:
Start: 04/21/21 End: 09/30/24 Due: 09/30/25

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401

Phase: N/A Priority: Normal
NCT ID: NCT06041165 Org: User:
Start: 08/31/23 End: 09/21/24 Due: 09/21/25

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04773951 Org: User:
Start: 04/12/21 End: 08/31/24 Due: 08/31/25

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Phase: N/A Priority: Normal
NCT ID: NCT04234620 Org: User:
Start: 02/15/20 End: 07/05/23 Due: 07/05/24

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT04605796 Org: User:
Start: 04/10/20 End: 12/31/22 Due: 12/31/23

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Phase: N/A Priority: Normal
NCT ID: NCT04929080 Org: User:
Start: 05/11/21 End: 03/06/23 Due: 03/06/24

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05751486 Org: User:
Start: 10/21/22 End: 12/30/25 Due: 12/30/26

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Phase: N/A Priority: Normal
NCT ID: NCT04603040 Org: User:
Start: 09/28/20 End: 03/31/23 Due: 03/31/24